$2.11 Billion is the total value of Camber Capital Management LP's 36 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | Sell | TESARO INC | $207,900,000 | +52.3% | 2,800,000 | -20.0% | 9.86% | +68.8% |
| MYL | Buy | MYLAN N V | $137,000,000 | -0.2% | 5,000,000 | +33.3% | 6.50% | +10.7% |
| AGN | Buy | ALLERGAN PLC | $133,660,000 | -22.0% | 1,000,000 | +11.1% | 6.34% | -13.6% |
| AGN | New | ALLERGAN PLCcall | $133,660,000 | – | 1,000,000 | +100.0% | 6.34% | – |
| UHS | UNIVERSAL HLTH SVCS INCcl b | $104,904,000 | -8.8% | 900,000 | 0.0% | 4.98% | +1.1% | |
| MCK | Buy | MCKESSON CORP | $96,661,000 | -2.8% | 875,000 | +16.7% | 4.59% | +7.7% |
| CELG | New | CELGENE CORP | $96,135,000 | – | 1,500,000 | +100.0% | 4.56% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS INC | $92,363,000 | +17.1% | 2,250,000 | +8.4% | 4.38% | +29.9% |
| PRGO | Buy | PERRIGO CO PLC | $85,250,000 | +20.4% | 2,200,000 | +120.0% | 4.04% | +33.5% |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $76,420,000 | – | 2,000,000 | +100.0% | 3.62% | – |
| BIIB | Sell | BIOGEN INC | $75,230,000 | -29.0% | 250,000 | -16.7% | 3.57% | -21.3% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $66,006,000 | -1.5% | 1,900,000 | +17.3% | 3.13% | +9.2% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $65,740,000 | -28.1% | 2,000,000 | +33.3% | 3.12% | -20.3% |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $58,416,000 | – | 600,000 | +100.0% | 2.77% | – |
| THC | Buy | TENET HEALTHCARE CORP | $55,705,000 | +26.3% | 3,250,000 | +109.7% | 2.64% | +40.0% |
| BMY | New | BRISTOL MYERS SQUIBB COcall | $51,980,000 | – | 1,000,000 | +100.0% | 2.47% | – |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $50,288,000 | -2.2% | 2,800,000 | +60.0% | 2.39% | +8.5% |
| BKD | Buy | BROOKDALE SENIOR LIVING | $50,250,000 | -21.4% | 7,500,000 | +15.4% | 2.38% | -12.8% |
| CAH | New | CARDINAL HEALTH INCcall | $44,600,000 | – | 1,000,000 | +100.0% | 2.12% | – |
| MNTA | Buy | MOMENTA PHARMACEUTICALS INC | $44,160,000 | -41.7% | 4,000,000 | +38.9% | 2.10% | -35.3% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $43,746,000 | – | 600,000 | +100.0% | 2.08% | – |
| AMAG | AMAG PHARMACEUTICALS INC | $40,254,000 | -24.0% | 2,650,000 | 0.0% | 1.91% | -15.8% | |
| MDCO | MEDICINES CO | $38,280,000 | -36.0% | 2,000,000 | 0.0% | 1.82% | -29.1% | |
| SRPT | New | SAREPTA THERAPEUTICS INC | $38,196,000 | – | 350,000 | +100.0% | 1.81% | – |
| THOR | New | SYNTHORX INC | $32,364,000 | – | 1,862,116 | +100.0% | 1.54% | – |
| ZYME | Buy | ZYMEWORKS INC | $31,797,000 | +47.5% | 2,166,000 | +57.8% | 1.51% | +63.6% |
| HCA | Sell | HCA HEALTHCARE INC | $31,113,000 | -77.6% | 250,000 | -75.0% | 1.48% | -75.2% |
| MYL | New | MYLAN N Vcall | $27,400,000 | – | 1,000,000 | +100.0% | 1.30% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $26,455,000 | -23.1% | 1,300,000 | +73.3% | 1.26% | -14.7% |
| ARNA | New | ARENA PHARMACEUTICALS INC | $19,475,000 | – | 500,000 | +100.0% | 0.92% | – |
| BHC | New | BAUSCH HEALTH COS INC | $18,470,000 | – | 1,000,000 | +100.0% | 0.88% | – |
| EGRX | EAGLE PHARMACEUTICALS INC | $11,749,000 | -41.9% | 291,600 | 0.0% | 0.56% | -35.6% | |
| DVA | New | DAVITA INC | $8,621,000 | – | 167,528 | +100.0% | 0.41% | – |
| ELGX | ENDOLOGIX INC | $6,659,000 | -62.5% | 9,300,000 | 0.0% | 0.32% | -58.4% | |
| STRO | SUTRO BIOPHARMA INC | $5,412,000 | -39.9% | 600,000 | 0.0% | 0.26% | -33.2% | |
| SGRY | Buy | SURGERY PARTNERS INC | $1,567,000 | -29.7% | 160,084 | +18.5% | 0.07% | -22.1% |
| KTWO | Exit | K2M GROUP HLDGS INC | $0 | – | -1,000,000 | -100.0% | -1.17% | – |
| EVHC | Exit | ENVISION HEALTHCARE CORP | $0 | – | -1,355,000 | -100.0% | -2.65% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -2,000,000 | -100.0% | -24.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.